Analysis: Omaxe Limited

NSE:OMAXE Realty - Construction & Contracting Market cap: ₹2.4K cr

Growth thesis

Omaxe develops residential and commercial real estate in Tier-2/3 cities, with residential sales comprising ~90% of revenue. Key growth drivers include Surajkund (800-1000 crores potential) and Lucknow Hi-Tech (400-500 crores FY17 target) launches, plus monetizing ₹600 crores of near-possession inventory over 9-12 months. Debt-equity improved to 0.46, with 10-15 bps cost-of-debt cuts expected in 2Qs. However, execution risks persist: Surajkund requires Haryana approvals, Lucknow Hi-Tech faces 6-12 month absorption lags, and OCP mall monetization needs 12-15 months. Over 2-3 years, 10-15% revenue growth depends on timely project completions and avoiding liquidity strain from working-capital cycles.

Why is Omaxe Limited stock rising?

  • Two major new launches planned: Surajkund project (JV with sales potential 800-1000 crores) and Lucknow Hi-Tech phase 1 (720 acres with first-year sales target 400-500 crores)
  • Affordable plotted projects in Yamuna Nagar, Rohtak, and Bahadurgarh under new Haryana 100 sq yard policy, expected to contribute ~150 crores in FY17
  • Commercial sales contribution expected to rise from 10% to 20% of mix, driven by Faridabad mixed-use development
  • RERA implementation seen as positive catalyst to restore buyer trust and benefit credible developers
  • Targeting 10-20% improvement in financial performance over next 1-2 years backed by new launches

Research report

companyname: Omaxe Limited ticker: OMAXE sector: Real Estate Omaxe Limited is a real estate development company built around a specific strategic niche: it dominates Tier 2 and Tier 3 cities in North and Central India by delivering projects on time in a market where most competitors do not. Founded in 1987 and listed on the NSE and BSE since 2007, the company has delivered over 140 million sq. ft. across 31 cities in 8 states as of FY25. The company's core competitive advantage is a trust prem...

Read the full report →

Catalysts

capex, regulatory approval, new product segment, acquisition inorganic

Growth guidance

No guidance

RS rating: 97 Stage: Stage 2

Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Omaxe Limited and 4,900+ companies.

Sign in
5-day free pass. No card required.
More in Realty - Construction & Contracting